Billion To One (BLLN) just delivered a massive 15% daily surge, effectively doubling its stock price just weeks after its IPO. Why is Wall Street obsessing over this new biotech player? It comes down to "Molecular Counting"—proprietary tech claiming to be 1,000x more sensitive than standard PCR—and a massive $500 million cash war chest.